NeuroDerm (NASDAQ: NDRM) is a clinical-stage pharmaceutical company that engages in developing products for the treatment of central nervous system (CNS) disorders. The company’s product candidates, which have completed phase IIa clinical trial, include ND0612H for the treatment of patients with severe Parkinson’s disease; and ND0612L for the treatment of patients with moderate stage of Parkinson’s disease. It is also developing ND0801, which is in phase IIa clinical trial for the treatment of cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimer’s disease, and schizophrenia; and ND0701, an apomorphine-based product candidate for the treatment of moderate to severe Parkinson’s disease. For more information, visit the company’s website at www.neuroderm.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
